Published in J Biol Inorg Chem on September 09, 2012
MutS homologue hMSH5: recombinational DSB repair and non-synonymous polymorphic variants. PLoS One (2013) 0.81
Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues. Bioorg Med Chem (2016) 0.78
The determination of the DNA sequence specificity of bleomycin-induced abasic sites. J Biol Inorg Chem (2016) 0.76
The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence. J Biol Inorg Chem (2017) 0.75
Mammalian telomeres end in a large duplex loop. Cell (1999) 12.12
A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A (1988) 11.81
Heterogeneity in telomere length of human chromosomes. Hum Mol Genet (1996) 6.55
DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer (2002) 4.69
TIN2, a new regulator of telomere length in human cells. Nat Genet (1999) 4.66
New antibiotics, bleomycin A and B. J Antibiot (Tokyo) (1966) 3.58
PTOP interacts with POT1 and regulates its localization to telomeres. Nat Cell Biol (2004) 3.33
Telomeric localization of TRF2, a novel human telobox protein. Nat Genet (1997) 3.23
Bleomycin-induced strand-scission of DNA. Mechanism of deoxyribose cleavage. J Biol Chem (1981) 3.00
T-loops and the origin of telomeres. Nat Rev Mol Cell Biol (2004) 2.54
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2. Curr Biol (2004) 2.45
Substrate nucleotide-determined non-templated addition of adenine by Taq DNA polymerase: implications for PCR-based genotyping and cloning. Biotechniques (1996) 2.02
Curing metastatic testicular cancer. Proc Natl Acad Sci U S A (2002) 1.92
Antitumor antibiotics: bleomycin, enediynes, and mitomycin. Chem Rev (2005) 1.91
On the mechanism of action of bleomycin: scission of DNA strands in vitro and in vivo. J Antibiot (Tokyo) (1969) 1.80
Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem (1981) 1.74
Cleavage of Nucleic Acids by Bleomycin. Chem Rev (1998) 1.60
Specificity of deoxyribonucleic acid cleavage by bleomycin, phleomycin, and tallysomycin. Biochemistry (1982) 1.36
Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res (1991) 1.34
Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress. Exp Cell Res (2004) 1.24
Comparison of the sequence specificity of bleomycin cleavage in two slightly different DNA sequences. Nucleic Acids Res (1985) 1.12
Mechanism of bleomycin action: in vitro studies. Life Sci (1981) 1.12
Crystal structure of DNA-bound Co(III) bleomycin B2: Insights on intercalation and minor groove binding. Proc Natl Acad Sci U S A (2008) 1.08
Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II). Proc Natl Acad Sci U S A (1983) 1.02
Purification of bleomycins. J Antibiot (Tokyo) (1966) 1.01
The sequence specificity of bleomycin-induced DNA damage in intact cells. J Biol Chem (1985) 0.97
Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acids Res (2000) 0.95
Genetic toxicology of bleomycin. Mutat Res (1978) 0.92
Telomere-driven genomic instability in cancer cells. Cancer Lett (2003) 0.90
Comet-FISH using peptide nucleic acid probes detects telomeric repeats in DNA damaged by bleomycin and mitomycin C proportional to general DNA damage. Mutagenesis (2004) 0.85
The sequence specificity of bleomycin damage in three cloned DNA sequences that differ by a small number of base substitutions. J Biol Chem (1988) 0.83
DNA structure influences sequence specific cleavage by bleomycin. Nucleic Acids Res (1993) 0.83
A survey of the sequence-specific interaction of damaging agents with DNA: emphasis on antitumor agents. Prog Nucleic Acid Res Mol Biol (1999) 0.82
Use of an automated capillary DNA sequencer to investigate the interaction of cisplatin with telomeric DNA sequences. Biomed Chromatogr (2011) 0.81
Influence of chromatin structure on bleomycin-DNA interactions at base pair resolution in the human beta-globin gene cluster. Biochemistry (1996) 0.80
The use of automated sequencing techniques to investigate the sequence selectivity of DNA-damaging agents. Chem Biol Drug Des (2012) 0.80
Bleomycins: new methods will allow reinvestigation of old issues. Curr Opin Chem Biol (2004) 0.79
Studies of metallobleomycins by electronic spectroscopy, electron spin resonance spectroscopy, and potentiometric titration. J Antibiot (Tokyo) (1979) 0.79
Studies on the action of mitomycin C and bleomycin on telomere lengths of human lymphocyte chromosomes. Int J Mol Med (2005) 0.78
Effect of bleomycin on interstitial telomeric sequences of immortalized Chinese hamster ovary cells. Mutat Res (2009) 0.77
The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. J Biol Inorg Chem (2011) 0.77
Chromatin structure at the 3'-boundary of the human beta-globin locus control region hypersensitive site-2. Int J Biochem Cell Biol (2001) 0.76
Human telomeric DNA sequences are a major target for the antitumour drug bleomycin. J Biol Inorg Chem (2011) 0.76
The sequence specificity of the anti-tumour drug, cisplatin, in telomeric DNA sequences compared with consecutive guanine DNA sequences. Anticancer Agents Med Chem (2012) 0.76
Induction of complete and incomplete chromosome aberrations by bleomycin in human lymphocytes. Mutat Res (2007) 0.76
A large "footprint" at the boundary of the human beta-globin locus control region hypersensitive site-2. Int J Biochem Cell Biol (2000) 0.76
Genomic and phylogenetic footprinting at the epsilon-globin silencer region in intact human cells. Biochim Biophys Acta (2004) 0.76
Footprinting the 'essential regulatory region' of the retinoblastoma gene promoter in intact human cells. Int J Biochem Cell Biol (2005) 0.76
The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol (1994) 0.75
A comparative analysis of bleomycin-induced incomplete chromosome elements in two mammalian cell lines using a telomeric PNA probe. Environ Mol Mutagen (2006) 0.75
Are telomeres a specific target for mutagenic attack by cytostatics in neoplastic cells? Int J Oncol (2005) 0.75
Detection of incomplete chromosome elements and interstitial fragments induced by bleomycin in hamster cells using a telomeric PNA probe. Mutat Res (2004) 0.75
FISH analysis of telomeric repeat sequences and their involvement in chromosomal aberrations induced by radiomimetic compounds in hamster cells. Mutat Res (2001) 0.75
The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T cell activation. J Immunol (2002) 1.02
Substituted 9-aminoacridine-4-carboxamides tethered to platinum(II)diamine complexes: chemistry, cytotoxicity and DNA sequence selectivity. J Inorg Biochem (2010) 1.01
The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta (2002) 0.91
The interaction of DNA-targeted 9-aminoacridine-4-carboxamide platinum complexes with DNA in intact human cells. Biochim Biophys Acta (2002) 0.85
The influence of chromatin structure on DNA damage induced by nitrogen mustard and cisplatin analogues. Chem Biol Drug Des (2010) 0.85
Use of an automated capillary DNA sequencer to investigate the interaction of cisplatin with telomeric DNA sequences. Biomed Chromatogr (2011) 0.81
Bleomycin DNA damage: Anomalous mobility of 3'-phosphoglycolate termini in an automated capillary DNA sequencer. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.77
Syntheses, crystal structure and cytotoxicity of diamine platinum(II) complexes containing maltol. J Inorg Biochem (2005) 0.77
The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells. Cell Mol Biol Lett (2011) 0.77
The interaction of peptide-tethered platinum(II) complexes with DNA. J Inorg Biochem (2003) 0.77
The potential of acridine carboxamide Pt complexes as anti-cancer agents : a review. Anticancer Agents Med Chem (2014) 0.77
The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. J Biol Inorg Chem (2011) 0.77
Human telomeric DNA sequences are a major target for the antitumour drug bleomycin. J Biol Inorg Chem (2011) 0.76
The interaction of cisplatin with a human telomeric DNA sequence containing seventeen tandem repeats. Bioorg Med Chem Lett (2012) 0.76
The DNA sequence selectivity of maltolato-containing cisplatin analogues in purified plasmid DNA and in intact human cells. J Inorg Biochem (2009) 0.76
Genomic and phylogenetic footprinting at the epsilon-globin silencer region in intact human cells. Biochim Biophys Acta (2004) 0.76
Footprinting the 'essential regulatory region' of the retinoblastoma gene promoter in intact human cells. Int J Biochem Cell Biol (2005) 0.76
The electrophoretic mobility of DNA fragments differing by a single 3'-terminal nucleotide in an automated capillary DNA sequencer. Biomed Chromatogr (2012) 0.76
The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells. Cancer Inform (2008) 0.75
Characterising the atypical 5'-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes. J Biol Inorg Chem (2014) 0.75
Chromatin structure at the flanking regions of the human beta-globin locus control region DNase I hypersensitive site-2: proposed nucleosome positioning by DNA-binding proteins including GATA-1. Biochim Biophys Acta (2004) 0.75
Site-directed mutagenesis of human papillomavirus 18 promoter elements and tissue-specific expression in cervical carcinoma cells. Virus Genes (2012) 0.75
Child-headed households in Rakai District, Uganda: a mixed-methods study. Paediatr Int Child Health (2014) 0.75
Child-headed households in Rakai District, Uganda: a mixed-methods study. Paediatr Int Child Health (2016) 0.75